+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06503614

Phase 2 Study of Durvalumab Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer Patients Unresponsive or Exposed to BCG

Led by John Sfakianos · Updated on 2026-10-05

60

Participants Needed

5

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of durvalumab and monalizumab in patients with non-muscle-invasive bladder cancer NMIBC who have either BCG-unresponsive or BCG-exposed carcinoma in situ CIS or high-grade papillary urothelial cancer. This phase 2 open-label study includes two groups one with CIS with or without high-grade papillary cancer, and another with high-grade papillary cancer without CIS. The study aims to assess treatment outcomes such as complete response at 6 months and monitor safety and survival outcomes over up to 36 months. Participants receive intravenous durvalumab and monalizumab at doses of 1500 mg each every 28 days for up to 13 cycles or one year, whichever comes first. Treatment continues until disease progression or unacceptable side effects occur. Both study groups receive the same dosing schedule and treatment administration. There is no placebo or randomization since all participants receive the study drugs. During the study, participants undergo regular visits for treatment and monitoring. Researchers will assess tumor response, treatment-related side effects, progression-free survival, overall survival, and other outcomes using clinical evaluations and laboratory tests. Participants must complete scheduled visits, examinations, and follow-ups as per protocol. The trial is expected to run until 2032, with primary outcome data collected by the end of 2027.

CONDITIONS

Brief Title

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Research Team

J

John Sfakianos, MD

A

Ahran Lee

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here